Literature DB >> 6661353

Assay-dependent kinetics of heparin: evidence for rapid in vivo activation of heparin.

F X McGowan, P V Nash, T D Bjornsson.   

Abstract

Multiple blood samples were collected over the first 15 min after an i.v. injection of 25 units/kg of heparin in four healthy subjects. Plasma heparin activity in each sample was determined by a chemical neutralization assay using polybrene and a bioassay based on activated partial thromboplastin time. Chemically assayed heparin declined much more rapidly than bioassayed heparin over the first 5-7 min after the dose. Subsequently, both heparin activity vs time curves declined with a similar terminal half-life. Slopes of the in vivo 1n APTT vs plasma heparin activity (determined by chemical neutralization) relationships were significantly greater than those of the corresponding in vitro relationships between 1n APTT vs heparin activity added to plasma. A possible explanation for these heparin assay differences is a rapid in vivo enhancement of the anticoagulant effect of heparin. How such enhancement may occur, however, is presently unclear.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661353      PMCID: PMC1428334          DOI: 10.1111/j.1365-2125.1983.tb02240.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Glycosaminoglycans and their binding to biological macromolecules.

Authors:  U Lindahl; M Höök
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

Review 2.  Heparin: new concepts relevant to clinical use.

Authors:  S Wessler; S N Gitel
Journal:  Blood       Date:  1979-04       Impact factor: 22.113

Review 3.  Heparins--anionic polyelectrolyte drugs.

Authors:  L B Jaques
Journal:  Pharmacol Rev       Date:  1979-06       Impact factor: 25.468

4.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

5.  Intersubject variability in the anticoagulant response to heparin in vitro.

Authors:  T D Bjornsson; K M Wolfram
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Appearance of heparin antithrombin-active chains in vivo after injection of commercial heparin and in anaphylaxis.

Authors:  S W Levy; L B Jaques
Journal:  Thromb Res       Date:  1978-09       Impact factor: 3.944

7.  Catabolism of low-dose heparin in man.

Authors:  J Dawes; D S Papper
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

8.  Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences.

Authors:  L R Whitfield; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

9.  Heparin kinetics determined by three assay methods.

Authors:  T D Bjornsson; K M Wolfram; B B Kitchell
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

Review 10.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.